The treatment strategy of blocking TSLP through a systematic approach has been clinically tested in a wide range of asthma patient populations and has shown positive results.[33] Recent studies have shown that the activity of NLRP3 inflammasome has a significant effect on the development of allergic airway inflammation, which is expected to become a new therapeutic target. The gene discussed is NLRP3; the disease is asthma.